Literature DB >> 21918117

Identification and immunological characterization of three potential vaccinogens against Cryptosporidium species.

Patricio A Manque1, Fernando Tenjo, Ute Woehlbier, Ana M Lara, Myrna G Serrano, Ping Xu, João M Alves, Ronald B Smeltz, Daniel H Conrad, Gregory A Buck.   

Abstract

Cryptosporidiosis is a ubiquitous infectious disease, caused by the protozoan parasites Cryptosporidium hominis and Cryptosporidium parvum, leading to acute, persistent, and chronic diarrhea with life-threatening consequences in immunocompromised individuals. In developing countries, cryptosporidiosis in early childhood has been associated with subsequent significant impairment in growth, physical fitness, and intellectual abilities. Currently, vaccines are unavailable and chemotherapeutics are toxic and impractical, and agents for immunoprophylaxis or treatment of cryptosporidiosis are a high priority. Availability of the genome sequences for C. hominis and C. parvum provides new opportunities to procure and examine novel vaccine candidates. Using the novel approach of "reverse vaccinology," we identified several new potential vaccine candidates. Three of these antigens--Cp15, profilin, and a Cryptosporidium apyrase--were delivered in heterologous prime-boost regimens as fusions with cytolysin A (ClyA) in a Salmonella live vaccine vector and as purified recombinant antigens, and they were found to induce specific and potent humoral and cellular immune responses, suggesting their potential as new vaccinogens against Cryptosporidium infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21918117      PMCID: PMC3209039          DOI: 10.1128/CVI.05197-11

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  41 in total

1.  Cryptosporidiosis surveillance--United States 1999-2002.

Authors:  Michele C Hlavsa; John C Watson; Michael J Beach
Journal:  MMWR Surveill Summ       Date:  2005-01-28

2.  TLR11 activation of dendritic cells by a protozoan profilin-like protein.

Authors:  Felix Yarovinsky; Dekai Zhang; John F Andersen; Gerard L Bannenberg; Charles N Serhan; Matthew S Hayden; Sara Hieny; Fayyaz S Sutterwala; Richard A Flavell; Sankar Ghosh; Alan Sher
Journal:  Science       Date:  2005-04-28       Impact factor: 47.728

3.  Expression of the recombinant fusion protein CP15-23 of Cryptosporidium parvum and its protective test.

Authors:  He Hong-Xuan; Chen Lei; Wang Cheng-Min; Zhou Kai; Tang Yi; Qin Xi-Ming; Duan Ming-Xing
Journal:  J Nanosci Nanotechnol       Date:  2005-08

4.  Nasal immunization of mice with Cryptosporidium parvum DNA induces systemic and intestinal immune responses.

Authors:  S Sagodira; S Iochmann; M N Mevelec; I Dimier-Poisson; D Bout
Journal:  Parasite Immunol       Date:  1999-10       Impact factor: 2.280

5.  Oral administration of a Salmonella enterica-based vaccine expressing Bacillus anthracis protective antigen confers protection against aerosolized B. anthracis.

Authors:  Margaret G M Stokes; Richard W Titball; Brendan N Neeson; James E Galen; Nicola J Walker; Anthony J Stagg; Dominic C Jenner; Joanne E Thwaite; James P Nataro; Leslie W J Baillie; Helen S Atkins
Journal:  Infect Immun       Date:  2006-12-04       Impact factor: 3.441

6.  Cryptosporidium parvum: the contribution of Th1-inducing pathways to the resolution of infection in mice.

Authors:  Humphrey N Ehigiator; Nina McNair; Jan R Mead
Journal:  Exp Parasitol       Date:  2006-08-22       Impact factor: 2.011

7.  NF-kappaB-mediated expression of iNOS promotes epithelial defense against infection by Cryptosporidium parvum in neonatal piglets.

Authors:  Jody L Gookin; Sophia Chiang; Jessica Allen; Martha U Armstrong; Stephen H Stauffer; Colleen Finnegan; Michael P Murtaugh
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2005-08-25       Impact factor: 4.052

8.  Oral and intraperitoneal administration of phosphorothioate oligodeoxynucleotides leads to control of Cryptosporidium parvum infection in neonatal mice.

Authors:  Mathieu Barrier; Sonia Lacroix-Lamandé; Roselyne Mancassola; Gaël Auray; Nelly Bernardet; Anne-Marie Chaussé; Satoshi Uematsu; Shizuo Akira; Fabrice Laurent
Journal:  J Infect Dis       Date:  2006-04-10       Impact factor: 5.226

9.  Induction of murine immune responses by DNA encoding a 23-kDa antigen of Cryptosporidium parvum.

Authors:  Humphrey N Ehigiator; Pablo Romagnoli; Jeffrey W Priest; W Evan Secor; Jan R Mead
Journal:  Parasitol Res       Date:  2007-05-09       Impact factor: 2.289

10.  Enhanced immunity to Plasmodium falciparum circumsporozoite protein (PfCSP) by using Salmonella enterica serovar Typhi expressing PfCSP and a PfCSP-encoding DNA vaccine in a heterologous prime-boost strategy.

Authors:  Magaly Chinchilla; Marcela F Pasetti; Sandra Medina-Moreno; Jin Yuan Wang; Oscar G Gomez-Duarte; Rick Stout; Myron M Levine; James E Galen
Journal:  Infect Immun       Date:  2007-05-14       Impact factor: 3.441

View more
  18 in total

1.  Systemic and Mucosal Immune Responses to Cryptosporidium-Vaccine Development.

Authors:  Jacob G Ludington; Honorine D Ward
Journal:  Curr Trop Med Rep       Date:  2015-09-01

Review 2.  Vaccines against human diarrheal pathogens: current status and perspectives.

Authors:  Nathalie Böhles; Nathalie Böhles; Kim Busch; Kim Busch; Michael Hensel; Michael Hensel
Journal:  Hum Vaccin Immunother       Date:  2014-05-26       Impact factor: 3.452

Review 3.  A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.

Authors:  William Checkley; A Clinton White; Devan Jaganath; Michael J Arrowood; Rachel M Chalmers; Xian-Ming Chen; Ronald Fayer; Jeffrey K Griffiths; Richard L Guerrant; Lizbeth Hedstrom; Christopher D Huston; Karen L Kotloff; Gagandeep Kang; Jan R Mead; Mark Miller; William A Petri; Jeffrey W Priest; David S Roos; Boris Striepen; R C Andrew Thompson; Honorine D Ward; Wesley A Van Voorhis; Lihua Xiao; Guan Zhu; Eric R Houpt
Journal:  Lancet Infect Dis       Date:  2014-09-29       Impact factor: 25.071

4.  Microarray analysis of the human antibody response to synthetic Cryptosporidium glycopeptides.

Authors:  Jamie Heimburg-Molinaro; Jeffrey W Priest; David Live; Geert-Jan Boons; Xuezheng Song; Richard D Cummings; Jan R Mead
Journal:  Int J Parasitol       Date:  2013-07-12       Impact factor: 3.981

Review 5.  Controlled Human Infection Models To Accelerate Vaccine Development.

Authors:  Robert K M Choy; A Louis Bourgeois; Christian F Ockenhouse; Richard I Walker; Rebecca L Sheets; Jorge Flores
Journal:  Clin Microbiol Rev       Date:  2022-07-06       Impact factor: 50.129

6.  Intranasal vaccination in mice with an attenuated Salmonella enterica Serovar 908htr A expressing Cp15 of Cryptosporidium: impact of malnutrition with preservation of cytokine secretion.

Authors:  James K Roche; Ana Lara Rojo; Lourrany B Costa; Ronald Smeltz; Patricio Manque; Ute Woehlbier; Luther Bartelt; James Galen; Gregory Buck; Richard L Guerrant
Journal:  Vaccine       Date:  2012-12-16       Impact factor: 3.641

7.  Potential Outer Membrane Protein Candidates for Vaccine Development Against the Pathogen Vibrio anguillarum: A Reverse Vaccinology Based Identification.

Authors:  Pallavi Baliga; Malathi Shekar; Moleyur Nagarajappa Venugopal
Journal:  Curr Microbiol       Date:  2017-11-08       Impact factor: 2.188

8.  Cryptosporidium parvum has an active hypusine biosynthesis pathway.

Authors:  Nimisha Mittal; Marie Morada; Pankaj Tripathi; V S Gowri; Swati Mandal; Alison Quirch; Myung Hee Park; Nigel Yarlett; Rentala Madhubala
Journal:  Mol Biochem Parasitol       Date:  2014-06-02       Impact factor: 1.759

9.  Identification and characterization of a novel calcium-activated apyrase from Cryptosporidium parasites and its potential role in pathogenesis.

Authors:  Patricio A Manque; Ute Woehlbier; Ana M Lara; Fernando Tenjo; João M Alves; Gregory A Buck
Journal:  PLoS One       Date:  2012-02-07       Impact factor: 3.240

10.  Genome-wide prediction of vaccine targets for human herpes simplex viruses using Vaxign reverse vaccinology.

Authors:  Zuoshuang Xiang; Yongqun He
Journal:  BMC Bioinformatics       Date:  2013-03-08       Impact factor: 3.169

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.